The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

Metastatic Prostate Cancer Market Research 2025-2035, Featuring Key Players Such as AstraZeneca, Merck, BMS, Daiichi Sankyo, Telix, Exelixis, Eli Lilly and Co, Zenith Epigenetics, MacroGenics - ...

Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell ...

The International Atomic Energy Agency has released a new report on analysis of samples of treated and diluted water discharged into the ocean from the Fukushima Daiichi Nuclear Power Plant.

Amazon announced the launch of the Amazon Web Services (AWS) Asia Pacific (Taipei) Region on Thursday, along with plans to invest more than $5 billion to support the construction, connection ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

ORCHARD (ClinicalTrials.gov identifier: NCT03944772) is a phase II, biomarker-directed platform study designed to characterize resistance mechanisms and evaluate novel drug combinations in patients ...

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2.

In September 2022, in the case of Daiichi Sankyo Company Limited v. Oscar Investment Limited and Ors., the Supreme Court of India ordered the arrest of promoters of Oscar Investment Limited (Oscar ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer, a new study found.